AbSTRACT. Avian leukosis virus subgroup J poses a great threat to the poultry industry in China. To reduce the economic losses, a quick method for detection of ALV-J antigen is required for diagnosis and identification of the congenitally transmitting hens. In this study, we report the production and evaluation of one monoclonal antibody (MAb) suitable for achieving these goals. The gp85 gene of avian leukosis virus subgroup J CAUHM01 China isolates was subcloned into the expression vectors pGEX-6p-1 and pET28a and successfully expressed in E. coli. After immunizing bALb/c mice with recombinant His-Jgp85 protein, splenic cells from immunized mice were fused with SP2/0 myeloma cells to produce hybridomas. We isolated and characterized one ALV-J gp85-specific MAb by determining its titer, affinity and IgG subclass. In addition, we performed epitope mapping and determined the epitope for the MAb 1E3 to be 81-92 aa of ALV-J gp85 protein (LPWDPQELDILG). Bioinformatics analysis and IFA studies revealed that this epitope is conserved among all ALV-J isolates and that this antibody could serve as a useful reagent for ALV-J detection and diagnosis. KEY WORDS: ALV-J gp85, epitope mapping, IFA, monoclonal antibody, myeloma cells.
In poultry, myelocytoma is an infectious tumorous disease induced by avian leukosis virus subgroup J (ALV-J) [3, 4] . This disease is characterized by growth inhibition, immune suppression and myelocytic neoplasm in affected animals. The major structural genes of ALV-J are gag, pol and env, which encode the proteins of virion group-specific antigens, an RNA-dependent DNA polymerase and envelope glycoproteins, respectively [2] . The virion envelope contains 2 glycoproteins encoded by the env gene: gp85 (SU), the viral surface knob-like structure that determines viral envelope subgroup specificity, and transmembrane protein gp37 (TM). Subgroups of ALV can be distinguished by the sequence and antigenicity of gp85 gene product.
Methods for detection and diagnosis of ALV-J have been established, such as virus isolation, PCR and ELISA. One of the ELISA methods is to detect p27 protein [1] , a group-specific antigen, but this method cannot differentiate subgroups of ALV. The other ELISA method is to detect antibodies against ALV-J gp85 protein [7] , a subgroup-specific antigen, and this method can distinguish the A/B and J subgroups. Although one ALV-J gp85 MAb [5] has been reported for detecting ALV-J antigen by IFA, the specificity, strength of affinity and epitope are still not clear.
In this study, we produced one monoclonal antibody against ALV-J gp85. We characterized the MAb by determining its titer, affinity and IgG subclass. In addition, we performed epitope mapping and determined the epitope for the MAb 1E3. Bioinformatics analysis and IFA studies revealed that this epitope is conserved among all ALV-J isolates and that this antibody could serve as a useful reagent for ALV-J detection and diagnosis.
MATERIALS AND METHODS

Viral strains and mice:
ALV subgroup reference strains NX0101 (ALV-J, Genbank: DQ115805), MAV-2 (ALVb, Genbank: L10923), and RAV-1 (ALV-A, Genbank: M19113) are kept in our laboratory; strains CAUGX01 (ALV-J, Genbank: HM640943), CAUHM01 (ALV-J, Genbank: HM640944), CAUSY01 (ALV-J, Genbank: HM640945) and bJN01 (ALV-A) were isolated and characterized by our laboratory. DF-1 cells and SP2/0 myeloma cells were acquired from ATCC. Eight week old bALb/c mice were maintained in our animal facility under the guidelines of our institution. All animal experiments were approved by the laboratory animal committee of the College of Veterinary Medicine, China Agricultural University.
Cloning and expression of recombinant proteins: Fulllength ALV-J gp85 gene was amplified from China CAUHM01 ALV-J isolates and cloned into BamHI/HindIII sites of pET28a and EcoRI/SalI sites of pGEX-6p-1 using following primers. pET28a forward:5'-GGATCCGCCAC-CATGGGAGTTCATCTGTTGCAACAACCA-3'. pET28a reverse:5'-AAGCTTGGCGCCTGCTACGGCGGTG-3'. pGEX-6p-1 forward:5'-GAATTCGGAGTTCATCTGTT-GCAAC-3'. pGEX-6p-1 reverse:5'-GTCGACTTAGC-GCCTGCTACGGCGGTGA-3'.
Truncated gp85 gene fragments were amplified and cloned into BamHI/XhoI sites of pGEX-6p-1 using fol- Recombinant proteins were expressed as His-or GSTtagged fusion proteins (60 and 45 kD for His-Jgp85 protein, 40 and 30 kD for GST-Jgp85 protein, 51 kD for GSTJgp85-A protein, 48 kD for GST-Jgp85-b protein, 33 kD for GST-Jgp85-C protein, 34 kD for GST-Jgp85-D protein) and purified by either nickel or GST affinity chromatography (Invitrogen, Carlsbad, CA, U.S.A.).
Mice immunization: Eight-week-old bALb/c mice were injected intraperitoneally (i.p.) with 50 µg of purified Histagged ALV-J gp85 proteins dissolved in 0.5 ml of PbS and emulsified in an equal volume of complete Freud's adjuvant (CFA). After an interval of 21 days, 20 µg of proteins emulsified in incomplete Freud's adjuvant (IFA) were used as a booster. The final i.p. injection was given 7 days later with 20 µg of His-Jgp85.
Cell fusion: In a Falcon 50 ml conical tube, 10 8 spleen cells were mixed with 2 × 10 7 SP2/0 myeloma cells. After centrifugation at 1,000 rpm for 10 min, the supernatant was removed, and 1 ml of prewarmed 50% PEG 4000 (polyethylene glycol, Roche, Germany) was slowly added to resuspend the pellet (within 1 min). Then, 1, 4 and 30 ml of prewarmed 10% DMEM was added for a period over 1, 3 and 2 min, respectively. After incubation for 10 min in a 37°C water bath, cells were centrifuged at 800 rpm for 10 min. The supernatant was removed, and the pellet was resuspended in HAT select culture media. Cell suspension was distributed to 96-well cell culture plates (Nunc) (100 µl/well) and placed in an incubator. On day 4, 100 µl fresh HAT media was added into each well. On day 8, the culture media was changed to HT culture media. On day 14, the culture media was changed to 10% DMEM media.
Hybridoma clone screening: After the fusion cells reached 50% confluency, the anti-Jgp85 activity in culture supernatants was tested with indirect ELISA. Briefly, culture supernatant was added to wells coated with 100 µl 1µg/ml purified GST-Jgp85 protein, and binding of the potential antibodies to the antigen was detected with HRP-labeled goat anti-mouse IgG (Beijing DingGuoChangSheng Biotechnology Co., Ltd., beijing, China). Cells in wells that produced detectable antibody were cloned 4 times by dilution on a feeder cell layer.
Ascites preparation and purification: Adult female bALb/c mice were given an i.p. injection of 0.5 ml of liquid petrolatum (beijing JingKeHongDa biotechnology Co., Ltd.). After 10-14 days, 1ml of hybridoma cells (1 × 10 6 cell/ml) were i.p inoculated into mice. The ascites fluids were collected 7-10 days later and centrifuged at 5,000 rpm for 10 min. The supernatants were stored at −80°C. The crude products of monoclonal antibody were further purified by saturated ammonium sulfate solution.
MAb IgG subclass characterization: The IgG subclass was determined by Mouse Monoclonal Antibody Isotyping Reagents (Sigma-Aldrich, Inc., St. Louis, MO, U.S.A.). A plate was coated with 100 µl of 1 µg/ml His-Jgp85. Supernatants of hybridomas were added and incubated at room temperature for 2 hr. After washing, isotype-specific antibodies were diluted 1:1,000 in PbS and incubated at room temperature for 30 min. After washing, HRP-labeled goat anti-mouse IgG (1:10,000) (Beijing DingGuoChangSheng biotechnology Co., Ltd.) was added and incubated for 15 min. After washing 3 times, TMb substrate (Sino-American biotechnology Co., Ltd., Zhengzhou, Henan, China) was added and incubated for 15 min at room temperature. The reaction was stopped by addition of 2 M sulfuric acid. Then, absorbance at OD 450 was obtained. The serial 2-fold dilutions of hybridoma culture supernatants and ascites were used to test the titer by indirect ELISA coated with 100 µl of 1 µg/ml His-Jgp85.
Affinity determination: Indirect ELISA was used to determine the affinity constant of the MAb. Briefly, the 96-well plates were coated with purified ALV-J gp85 proteins at 0.1, 0.5 and 1.0 µg per well. Purified monoclonal antibodies were 2-fold diluted from 500 to 0.24 µg/ml. MAbs were added in coated wells with three antigen concentrations and incubated at 37°C for 1 hr. After extensive washing with PBST, HRP-conjugated goat anti-mouse IgG (1:1,000) was used as the second antibody and incubated at 37°C for 30 min. TMb substrate was added for color reaction. Absorbance at OD 450 was obtained using a plate reader, and values were plotted against the amounts of MAbs used. The MAbs concentration corresponding to 50% of the highest OD values (OD max ) was used in the formula below to calculate the affinity constant of the MAbs. K= (n−1)/2(nAb'−Ab) Ab and Ab' represent the antibody concentration corresponding to mol/l of the 50% OD max value when the coating antigen concentrations were 0.1 and 1.0 µg/well, respectively (n=10; 1 µg/0.1 µg).
Analysis of MAb recognition sites and epitope mapping: To determine the recognition site of 1E3, we first used this MAb to probe with four fragments of GST-tagged Jgp85 fusion proteins. Then, the recognition epitope was further characterized by epitope mapping using synthetic peptides. Briefly, sets of 12 mer overlapping peptides with 3 amino acid shifts were synthesized by CHI Scientific, Inc. (Maynard, MA, U.S.A.). Peptide powders were resuspended in DMSO and used to coat 96-well plates at 10 ng/well. Indirect ELISA was used as described above to determine the reactivity to MAb 1E3.
Indirect immunofluorescent assay (IFA): DF-1 cells were grown on a 96-well plate with culture media supplemented with 10% FCS until they reached 50 to 60% confluency. After two washes with PbS, virus was diluted with culture media supplemented with 1% FCS and inoculated onto the DF-1 cell monolayer. Two hours later, infected cells were washed twice with PbS and supplied with culture media supplemented with 1% FCS. After 3 to 4 days of culture, infected cells were washed with PbS for 3 min. Then, cells were fixed with precooled acetone-ethanol (6:4) and washed twice for 3 min with PbS. Fixed cells were stained with 1E3 (1:10,000) for 45 min at 37°C. Then, diluted Rabbit anti-mouse IgG/FITC (Beijing DingGuoChangSheng Biotechnology Co., Ltd.) (1:200) was added into the plate and incubated for 30 min at 37°C. After final washes, the plate was mounted with glycerol-PbS (1:1) and examined under an inverted fluorescence microscope (Olympus CKX41-F32FL).
RESULTS
Expression and purification of GST-Jgp85 and HisJgp85:
In order to generate an ALV-J gp85-specific MAb, His-tagged and GST-tagged Jgp85 recombinant proteins were expressed and purified from a prokaryotic expression system as described in Materials and Methods. SDS-PAGE gel analysis indicated that both His-tagged Jgp85 and GSTtagged Jgp85 fusion proteins were well expressed in E. coli and purified by affinity chromatography under native conditions ( Fig. 1A and 1b) . both GST-Jgp85 and His-Jgp85 fusion proteins showed another C terminal truncated form, which was confirmed by Western blot analysis using ALV-Jpositive serum (Fig. 1C and 1D) .
Generation and characterization of MAbs:
In order to avoid a cross-reaction with anti-His-tag antibody, Histagged Jgp85 was used as an immunization antigen and GST-tagged Jgp85 was used as a screening antigen. After 3 rounds of immunizations, splenic cells from immunized mice were fused with SP2/0 myeloma cells. The fusion rate of hybridoma cells was as high as 93%. Until the fusion cells reached 50% confluency, the anti-GST-Jgp85 activity in culture supernatant was tested by indirect ELISA as described in Materials and Methods. Then cells in the positive well were further diluted to isolate a single clone. After 4 rounds of limited dilution cloning, one Jgp85 monoclonal hybridoma was acquired and named as 1E3.
To acquire abundant and high-titer ascites, hybridoma cells were inoculated into the mice, and ascites fluids were collected 7-10 days later. The ascites were purified by saturated ammonium sulfate solution. The result of SDS-PAGE showed that there were two specific protein bands, corresponding to the heavy chain (50 kD) and the light chain (25 kD) of each MAb. IgG subclass analysis revealed that the MAb belonged to IgG2b, and the titer of the ascites was 2 × 10 6 . The affinity of the MAb was measured according to method established by Schots et al. [6] . The affinity constant K value for MAb 1E3 was 5.86 × 10 8 . Generally, MAb with a K value within the range of 10 7 -10 12 was considered to be a high-affinity antibody. These results indicated that we have successfully developed one high-affinity MAb against ALV-J gp85.
Determination of Mab 1E3 recognizing epitope: In order to determine the specificity and potential application of the highest affinity MAb 1E3 as a ALV-J diagnostic reagent, we decided to map the 1E3 recognizing epitope. First, we expressed two overlapping fragments of ALV-J gp85 gene using pGEX-6p-1 vector. pGEX-6p-1-Jgp85-A and pGEX6p-1-gp85-b encoded 1-229 and 113-307 aa of Jgp85 protein, respectively. Recombinant GST-Jgp85-A and GSTJgp85-b were expressed successfully in E.coli with molecular weights of 47 and 51 kD ( Fig. 2A) . Western blot analysis revealed that the antibody 1E3 recognized epitopes within the gp85-A protein (Fig. 2b) . Next, Jgp85-A was further truncated into fragments C (33 kD) and D (34 kD), which encode 1-68 and 35-112 aa of Jgp85 protein. As shown in Fig. 2C and 2D , both recombinant proteins were expressed well in E. coli, and 1E3 only recognize GST-Jgp85-D. These results demonstrated that the 1E3 recognizing epitope is located within 68-112 aa of the ALV-J gp85 protein.
For precise mapping of this epitope, we synthesized twelve 12-mer peptides with 9 overlapping amino acids, which covered 68-112 aa of ALV-J gp85 protein (Fig. 3A) . Indirect ELISA showed that 1E3 only reacted with peptide 5 (Fig. 3B) . Thus, we identified that the target sequence of MAb 1E3 is LPWDPQELDILG, which corresponds to 81-92 aa of ALV-J gp85.
MAb 1E3 specifically reacts with subgroup J leukosis virus: We analyzed the antigen-binding site of 1E3 from dif- ferent subgroups (Fig. 4A ) and different ALV-J isolates (Fig.  4b) . bioinformatics analysis showed that gp85 from ALV subgroup A, b, C and D had no homology with this MAb 1E3 recognizing epitope, and endogenous ALV-E gp85 shares low similarity with this epitope (Fig. 4A ). In addition, this epitope is conserved among all ALV-J isolates. Only one amino acid is different at locations 82 and 87 of the CAUGX01 and NX0101 isolates, respectively. Next, we tested the specificity of Mab 1E3 experimentally. We used MAb 1E3 to detect ALV isolates from different subgroups, including RAV-1 (ALV-A), AMV-2 (ALV-b) and four ALV-J isolates (CAUHM01, CAUGX01, CAUSY01 and NX0101) by IFA. As expected, MAb 1E3 specifically reacted with all ALV-J isolates but not isolates from other subgroups (Fig. 5) . These results indicated that the MAb 1E3 recognizes amino acids within positions 81-92 except for 82 and 87 of ALV-J gp85.
DISCUSSION
In this study, we produced one monoclonal antibody against the ALV-J gp85 protein by using a bacterially expressed recombinant protein as the antigen. Although ALV-J gp85 is a glycoprotein and the prokaryotic expression system lacks a glycosylation process, E. coli-expressed Jgp85 preserved at least part of its antigenicity.
by analyzing the reactivity to truncated Jgp85 proteins and synthetic peptides, we determined the epitope of MAb 1E3 as LPWDPQELDILG, which corresponds to 81-92 aa of ALV-Jgp85 protein. To our knowledge, this is the first reported ALV-Jgp85-specific MAb with a defined epitope. Bioinformatics and IFA analysis confirmed the specificity and potential application of this MAb, although reactivity of the MAb to ALV-E was not examined. Endogenous ALV-D gp85 shared a low degree of similarity with the defined 1E3 epitope, but whether 1E3 reacts with endogenous ALV-E gp85 still requires further investigation.
In this study, we obtained one monoclonal antibody against the ALV-Jgp85 protein. The MAb has high affinity to ALV-Jgp85 and belongs to the IgG2b subclass. We also defined the epitope recognized by MAb 1E3. We were capable of using this MAb to detect and differentiate ALV-J from other ALV subgroups. This will provide a powerful tool for studying the prevalence of ALV-J in China and development of an ALV-J antigen detection kit.
